Healthcare Industry News: HSMN NewsFeed
News Release - October 19, 2017
Bayer Appoints Jennifer Brendel to Vice President, Head of U.S. Consumer Health CommunicationsWHIPPANY, N.J., Oct. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Bayer is proud to announce today the appointment of Jennifer Brendel to Vice President of Communications for the company's Consumer Health Division in the United States.
Brendel, who spent the last 15 months leading Bayer's Pharmaceutical Product Communications, will be responsible for developing and executing external and internal communications strategies for some of the most well-known Consumer Health brands in the world, such as Aleve®, Coppertone® and Aspirin.
Brendel will report directly to Raymond F. Kerins, Jr., Senior Vice President and Head of Communications, Government Relations and Policy for Bayer, and will be the newest member of the U.S. Communications, Government Relations and Policy Leadership Team.
"I am excited to have Jen take on this new leadership role as we continue to raise Bayer's profile in the United States" Kerins said. "Jen is a tremendous communications professional. Her years of experience managing major Consumer brands plus her knowledge of our company's strategy and values makes her perfectly suited to lead communications for the largest Consumer Health company in the U.S., Bayer's largest and fastest growing market."
Prior to coming to Bayer, Brendel spent almost a decade at Pfizer in Marketing and Communications roles in the United States and Europe, most recently serving as the Global Marketing Lead for Celebrex® *. Prior to that, she spent three years leading communications for Pfizer's Rx-to-OTC switch portfolio. In this role Jen led activities to raise awareness about the importance of self-care and increase receptivity to first-in-class over-the-counter medicines. Before joining Pfizer, Brendel spent time at several leading communications agencies in New York and Los Angeles and as a pharmaceutical sales representative.
"I am honored to begin this new opportunity here at Bayer at such a critical time of growth for the company," Brendel said. "Bayer's Consumer Health brands are some of the most cherished and trusted in the world. I look forward to helping these brands tell their stories, connect with consumers and continue to improve millions of lives here in the United States."
Brendel holds a BA in Journalism from the University of Central Florida and is a resident of Hoboken, NJ.
* Celebrex is a registered trademark of Pfizer Inc.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Social Media Channels
- Facebook: facebook.com/BayerUnitedStates
- Twitter: twitter.com/BayerUS
- Instagram: instagram.com/BayerUS
- YouTube: youtube.com/BayerUS
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsPhase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority
Bayer Appoints Dr. Sharon James Head of Global Innovation & Development for Consumer Health
Bayer Expands Oncology Organization with Two New Leadership Team Appointments